Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: death · dialysis vascular access outcomes in AVG patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: hospitalisation · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: hospitalisation compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: hospitalisation · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: hospitalisation compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review
Adverse effects (cardiac) · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…
It is very uncertain whether omega‐3 fatty acids and antioxidants changes cardiac adverse events (study author reported anytime during study… compared with placebo or standard nutrition (very low certainty).
1 finding from 1 review
Study author‐reported adverse events · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…
It is very uncertain whether omega‐3 fatty acids and antioxidants changes total number of adverse events (study author reported anytime during… compared with placebo or standard nutrition (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · adults (aged 18 years or older), mechanically ventilated participants with ARDS as defined by the Berlin definition of ARDS or, for older…
It is very uncertain whether omega‐3 fatty acids and antioxidants changes gastrointestinal adverse events (study author reported anytime… compared with placebo or standard nutrition (very low certainty).
1 finding from 1 review
Adverse events ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found